The year-long Rimonabant in Obesity-Diabetes study, a multi-center trial which enrolled 1,000 obese patients with type 2 diabetes, will be the last of the four major Acomplia studies to report trial results before U.S. and European regulators are expected to act on Sanofi-Aventis’ application to bring the drug to market.

In this trial, researchers compared weight-loss, improvements in metabolic variables, and reduction in cardiovascular risk factors for obese diabetics who took Acomplia compared to those on a placebo.

RIO-Diabetes, the multicenter, randomized, double-blind, placebo-controlled trial

of rimonabant in overweight/obese type 2 patients, evaluated weight loss, metabolic

variables and cardiovascular risk reduction; and findings from the Diabetes Prevention

Program follow-up studies indicate that complications can occur even earlier than we

previously thought – well before the actual cut-point for diagnosing type 2 diabetes

RIO-Diabetes, the multicenter, randomized, double-blind, placebo-controlled trial

of rimonabant in overweight/obese type 2 patients, evaluated weight loss, metabolic

variables and cardiovascular risk reduction; and findings from the Diabetes Prevention

Program follow-up studies indicate that complications can occur even earlier than we

previously thought – well before the actual cut-point for diagnosing type 2 diabetes

RIO-Diabetes, the multicenter, randomized, double-blind, placebo-controlled trial

of rimonabant in overweight/obese type 2 patients, evaluated weight loss, metabolic

variables and cardiovascular risk reduction; and findings from the Diabetes Prevention

Program follow-up studies indicate that complications can occur even earlier than we

previously thought – well before the actual cut-point for diagnosing type 2 diabetes

Announcement of the results of the RIO-Diabetes trial is slated for a symposium on “Late-Breaking Clinical Trials” scheduled to be held at 2 pm PDT June 12th.

Researchers have hinted privately to reporters that the results are consistent with the highly encouraging results from their three studies reported earlier — RIO-North America, RIO-Europe and RIO-Lipids.

The fact that the results are going to be presented at the highest-profile symposium at the American Diabetes Association meeting — only weeks after Sanofi filed for approval of the drug with the U.S. Food and Drug Administration and European regulators — also strongly suggests more positive news is forthcoming.

More related articles: Acomplia news report

                                     Rimonabant acomplia competitor